

Supplemental Digital Content 2. Comparison of Subjects With a Pneumococcal IgG Antibody Concentration ≥ 0.35 $\mu\text{g/mL}$ 1 and 2 Years After the Last Vaccine Dose, Evaluable Immunogenicity Population

Serotype	1-Year Follow-up			2-Year Follow-up		
	Preterm n ^a =78–80 %	Term n ^a =78–80 %	Difference ^b (95% CI)	Preterm n ^a =65–71 %	Term n ^a =63–71 %	Difference ^b (95% CI)
PCV7 serotypes						
4	36.3	53.2	-16.9 (-32.0 to -1.1)	20.0	31.0	-11.0 (-25.5 to 3.7)
6B	95.0	97.5	-2.5 (-10.0 to 4.3)	90.0	97.1	-7.1 (-16.8 to 1.3)
9V	71.3	91.3	-20.0 (-32.2 to -7.0)	81.7	87.1	-5.5 (-17.9 to 6.9)
14	92.4	95.0	-2.6 (-11.3 to 5.7)	81.4	91.5	-10.1 (-22.2 to 1.5)
18C	43.8	77.2	-33.5 (-47.4 to -18.5)	46.4	74.6	-28.3 (-43.4 to -11.6)
19F	93.8	96.2	-2.5 (-10.6 to 5.2)	87.3	95.7	-8.4 (-18.8 to 1.1)
23F	69.6	92.5	-22.9 (-35.0 to -10.0)	83.1	95.8	-12.7 (-23.8 to -2.4)
Additional PCV13 serotypes						
1	57.7	72.5	-14.8 (-29.7 to 0.3)	48.6	52.2	-3.6 (-20.5 to 13.4)
3	11.5	25.6	-14.1 (-26.6 to -1.6)	20.0	33.3	-13.3 (-28.6 to 2.5)
5	89.9	93.6	-3.7 (-13.4 to 5.5)	87.0	95.7	-8.7 (-19.6 to 0.9)
6A	92.5	98.7	-6.2 (-14.3 to 0.5)	91.5	98.6	-7.0 (-16.0 to 0.4)
7F	86.1	93.8	-7.7 (-18.0 to 2.0)	78.9	80.0	-1.1 (-15.0 to 12.6)
19A	91.3	98.8	-7.5 (-15.9 to -0.6)	94.4	100.0	-5.6 (-13.8 to -0.2)

IgG=immunoglobulin G; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine.

^an=number of subjects with a determinate IgG antibody concentration to the given serotype.

^bDifference in proportions: preterm minus term, expressed as a percentage